Evidence map›Paper›PMID 34375343›Full record

ArticlePloS one2021

To achieve 95-95-95 targets we must reach men and youth: High level of knowledge of HIV status, ART coverage, and viral suppression in the Botswana Combination Prevention Project through universal test and treat approach.

Refeletswe Lebelonyane, Pamela Bachanas, Lisa Block, Faith Ussery, Mary Grace Alwano, Tafireyi Marukutira, Shenaaz El Halabi, Michelle Roland, William Abrams, Gene Ussery and 9 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01965470 (Botswana Combination Prevention Project), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01965470 phase4completednot on this map

Botswana Combination Prevention Project: -Evaluation Protocol (Protocol #1): Research Design and Impact Evaluation -Closed Clinical Cohort Protocol (Protocol #3) Implementation, Monitoring and Evaluation of Combination HIV Prevention Interventions in Rural and Peri-Urban Communities in Botswana

TypeinterventionalSponsorCenters for Disease Control and PreventionRan2013 to 2018ConditionsHIVArmsCombination Prevention, Enhanced Care
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. The role of machine learning in HIV risk prediction.Frontiers in reproductive health · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

Refeletswe LebelonyaneMinistry of Health and Wellness, Gaborone, Botswana.ORCID 0000-0002-9838-2419
Pamela BachanasU.S. Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Lisa BlockNorthrop Grumman, Atlanta, GA, United States of America.
Faith UsseryU.S. Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Mary Grace AlwanoU.S. Centers for Disease Control and Prevention, Gaborone, Botswana.
Tafireyi MarukutiraU.S. Centers for Disease Control and Prevention, Gaborone, Botswana.ORCID 0000-0003-1142-6114
Shenaaz El HalabiMinistry of Health and Wellness, Gaborone, Botswana.
Michelle RolandU.S. Centers for Disease Control and Prevention, Gaborone, Botswana.
William AbramsU.S. Centers for Disease Control and Prevention, Gaborone, Botswana.
Gene UsseryNorthrop Grumman, Atlanta, GA, United States of America.
James A MillerNorthrop Grumman, Atlanta, GA, United States of America.
Shahin LockmanHarvard T.H. Chan School of Public Health, Boston, MA, United States of America.
Tendani GaolatheBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Molly Pretorius HolmeBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Shannon HaderUNAIDS, Geneva, Switzerland.
Lisa A MillsU.S. Centers for Disease Control and Prevention, Gaborone, Botswana.
Kathleen WirthHarvard T.H. Chan School of Public Health, Boston, MA, United States of America.
Naomi BockU.S. Centers for Disease Control and Prevention, Atlanta, GA, United States of America.ORCID 0000-0001-7537-6270
Janet MooreU.S. Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Centers for Disease Control and Prevention · USNorthrop Grumman (United States) · USBotswana Harvard AIDS Institute Partnership · BWHarvard University · USMinistry of Health · BWJoint United Nations Programme on HIV/AIDS · CH

Funding

CGH CDC HHS U01 GH000447CGH CDC HHS U2G GH000073CGH CDC HHS U2G GH000419CGH CDC HHS U2G GH001911PEPFAR
6 · The paper itself

Abstract

backgroundIncreasing HIV treatment coverage is crucial to reducing population-level HIV incidence.

methodsThe Botswana Combination Prevention Project (BCPP) was a community randomized trial examining the impact of multiple prevention interventions on population-level HIV incidence and was conducted from October 2013 through June 2017. Home and mobile campaigns offered HIV testing to all individuals ≥ age 16. All identified HIV-positive persons who were not on antiretroviral therapy (ART) were referred to treatment and tracked to determine linkage to care, ART status, retention in treatment, and viral suppression.

resultsOf an estimated total of 14,270 people living with HIV (PLHIV) residing in the 15 intervention communities, BCPP identified 13,328 HIV-positive persons (93%). At study start, 10,703 (80%) of estimated PLHIV knew their status; 2,625 (20%) learned their status during BCPP, a 25% increase with the greatest increases occurring among men (37%) and youth (77%). At study start, 9,258 (65%) of estimated PLHIV were on ART. An additional 3,001 persons started ART through the study. By study end, 12,259 had initiated and were retained on ART, increasing coverage to 93%. A greater increase in ART coverage was achieved among men (40%) compared to women (29%). Of the 11,954 persons who had viral load (VL) test results, 11,687 (98%) were virally suppressed (HIV-1 RNA ≤400 copies/mL). Overall, 82% had documented VL suppression by study end.

conclusionsKnowledge of HIV-positive status and ART coverage increased towards 95-95 targets with universal testing, linkage interventions, and ART. The increases in HIV testing and ART use among men and youth were essential to reaching these targets. CLINICAL TRIAL NUMBER: NCT01965470.

Indexed as

Antiretroviral Therapy, Highly ActiveHealth Knowledge, Attitudes, PracticeHIV TestingAdolescentAdultBotswanaFamily CharacteristicsFemaleHIV InfectionsHumansMaleMiddle AgedYoung Adult

Identifiers

PMID34375343
PMCPMC8354449
OpenAlexW3187142408

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.